# Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation

> **NCT06108414** · PHASE4 · RECRUITING · sponsor: **China National Center for Cardiovascular Diseases** · enrollment: 4374 (estimated)

## Conditions studied

- Atrial Fibrillation
- Anticoagulant Adverse Reaction
- Stroke
- Major Adverse Cardiac Events

## Interventions

- **DRUG:** low-dose rivaroxaban
- **DRUG:** Standard-dose rivaroxaban

## Key facts

- **NCT ID:** NCT06108414
- **Lead sponsor:** China National Center for Cardiovascular Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 4374 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06108414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06108414, "Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06108414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*